Clinical Trials Logo

Metabolic Syndrome X clinical trials

View clinical trials related to Metabolic Syndrome X.

Filter by:

NCT ID: NCT00379171 Completed - Obesity Clinical Trials

Milk Types and Fish Oil in 9- to 12-Month-Old Infants

Start date: May 2003
Phase: N/A
Study type: Interventional

The objective of this intervention study is to examine the effect of whole cow's milk versus infant formula as primary milk sources with or without supplements of n-3 LCPUFA for growth, nutritional status, development, risk factors for later diseases and the impact on the intestinal microbiota and inflammation in 9 - 12 months old infants.

NCT ID: NCT00378859 Completed - Metabolic Syndrome Clinical Trials

The Effect of Milk and Meat on IGFs in Prepubertal Boys

Start date: November 2000
Phase: N/A
Study type: Interventional

The objective of the study is to examine whether a 7-day high protein intake from either milk or meat in healthy, prepubertal children can increase fasting levels of serum IGF-I, IGFBP-3 and IGF-I/IGFBP-3 as well as insulin, glucose and HOMA insulin reststance, HOMA beta cell function and amino acids.

NCT ID: NCT00370305 Completed - Metabolic Syndrome Clinical Trials

11ß-HSD1 and Metabolic Syndrome

Start date: May 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the insulin sensitizing effects of rosiglitazone were accompanied by changes in 11ß-HSD1 expression and activity in different tissues. Furthermore the metabolic and hormonal effects of PPAR gamma stimulation by rosiglitazone will be analysed in several tissues.

NCT ID: NCT00364221 Completed - Metabolic Syndrome Clinical Trials

Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome

Start date: November 2004
Phase: Phase 4
Study type: Interventional

The metabolic syndrome is a collection of health risks that includes obesity, high blood pressure, high triglycerides, high blood sugar, low good cholesterol, and resistance to insulin. The purpose of this study is to find out if the medication, rosiglitazone, influences levels of fat cell proteins and alters insulin resistance in nondiabetic persons with the metabolic syndrome. This is an early step to see if a medication, such as rosiglitazone, will be beneficial in people who have the metabolic syndrome.

NCT ID: NCT00363181 Completed - Insulin Resistance Clinical Trials

Side Effects of Antipsychotic Medications

Start date: April 2006
Phase:
Study type: Observational

Medications like olanzapine have been associated with the development of weight gain and diabetes in some patients. It is not known if the increased risk of developing diabetes is a direct effect on insulin or simply related to weight gain. We hope to learn in this study whether or not olanzapine directly slows down insulin secretion from the pancreas, thereby increasing the risk of developing diabetes.

NCT ID: NCT00362908 Completed - Dyslipidemias Clinical Trials

Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome

Start date: September 2006
Phase: N/A
Study type: Interventional

The metabolic syndrome consists of five concurrent conditions which increase risk of heart disease, stroke, and diabetes. Persons with the metabolic syndrome usually have high triglyceride and low HDL levels and are overweight. Low fat, high carbohydrate diets may not provide the same cholesterol-lowering benefits to obese individuals as they do to non-obese individuals. The purpose of this study is to compare the effects of a low fat, high carbohydrate diet versus a moderate fat, moderate carbohydrate diet on the heart, blood vessels, and cholesterol levels in individuals with metabolic syndrome.

NCT ID: NCT00362440 Completed - HIV Lipodystrophy Clinical Trials

Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome

Start date: August 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether patients with HIV lipodystrophy (fat wasting) benefit from taking the combination of two drugs, one insulin sensitizer (either metformin or pioglitazone, both diabetes drugs) and leptin (a natural hormone produced by your fat cells). Our hope is that they will improve sugar and fat metabolism and positively affect the body fat changes you have noticed while taking HAART.

NCT ID: NCT00362128 Completed - Hypertension Clinical Trials

Cardiovascular Disease Risk Factors in Chinese American Immigrants

CHA-CHA
Start date: January 2007
Phase:
Study type: Observational

The Chinese population is currently the fastest growing ethnic group in New York City (NYC). Research has shown that Chinese immigrants living in NYC have higher rates of cardiovascular disease (CVD) than individuals in China. This study will evaluate the effect that acculturation has on health habits and CVD risk factors in Chinese immigrants living in NYC.

NCT ID: NCT00356785 Completed - Obesity Clinical Trials

Changes in Body Composition and Metabolic Risk Parameters by Life Style Intervention.

Start date: January 2001
Phase: N/A
Study type: Interventional

Eligible overweight and obese persons will be randomized to one of three controlled groups: 1 group of participants is treated by health education for life style intervention only. The other 2 groups will be included in a dietary program with an individually dosed food supplement (Almased®) for an initial weight reduction for a period of 6 weeks. The following 18 weeks represent the most important phase of weight loss and attitude, the participants take part in 2 different interventions according to their randomization. One group will continue the dietary program, one group will try to achieve and maintain weight reduction by continuing the initial dietary program together with an additional physical activity program. For all intervention groups the following 6 months aim at a further stabilization of weight and attitude, now without defined guidelines of intervention but with the intention to continue the so far practiced change in life style. All participants will be supplied with adequate information and material concerning the desired change in life style.

NCT ID: NCT00352287 Completed - Obesity Clinical Trials

Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults

Start date: March 2003
Phase: Phase 4
Study type: Interventional

The purpose of the study was to determine the effects of growth hormone and an insulin sensitizer drug in pre-diabetic adults with excessive amounts of abdominal fat. Participants received a combination of two drugs: (1) recombinant human growth hormone (or its placebo) and (2) pioglitazone (or its placebo). We measured the abdominal fat content and blood sugar levels of participants before and after 40 weeks of treatment.